Registration Dossier

Administrative data

Description of key information

STOT SE 1 H370

In humans, desipramine hydrochloride induces central nervous system (CNS) and cardiovascular effects at therapeutic (0.5-2 mg/kg) and supratherapeutic doses. CNS effects are not limited to dizziness and vertigo, and include hallucinations due to the anticholinergic properties of the substance as well as seizures. Cardiovascular effects include tachycardia, QRS widening and hypotension.

[Antidepressants, tricyclic - Poisindex(R) Management]

STOT SE 3 H336

Dizziness and somnolence are common adverse effects (DrugPoints System).

Dizziness

a) Tricyclic antidepressants have been known to cause dizziness. Because desipramine is a tricyclic antidepressant, dizziness may occur with this drug (Prod Info NORPRAMIN(R) oral tablets, 2009).

Somnolence

a) Tricyclic antidepressants have been known to cause drowsiness. Because desipramine is a tricyclic antidepressant, drowsiness may occur with this drug (Prod Info NORPRAMIN(R) oral tablets, 2009).

[DRUGDEX® System: Klasco RK: DRUGDEX® System. Truven Health Analytics, Greenwood Village, Colorado.]

Even if the CNS mentioned adverse effects (i.e. dizziness, somnolence and CNS depression) were observed at therapeutic dose, and may have limited importance for industrial chemicals and their safety assessment, the substance is classified as STOT SE 3 H336, since it is not possible to establish if these type of effects are relevant at lower doses.

Additional information